Neuronetics, Inc. (NASDAQ:STIM) CEO Sells $45,907.80 in Stock

Neuronetics, Inc. (NASDAQ:STIM) CEO Keith J. Sullivan sold 24,162 shares of the stock in a transaction on Thursday, July 18th. The stock was sold at an average price of $1.90, for a total value of $45,907.80. Following the transaction, the chief executive officer now owns 1,324,354 shares of the company’s stock, valued at approximately $2,516,272.60. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Neuronetics Stock Performance

Shares of STIM stock opened at $1.88 on Thursday. The company’s fifty day simple moving average is $1.97 and its two-hundred day simple moving average is $3.03. Neuronetics, Inc. has a 1 year low of $1.03 and a 1 year high of $5.07. The company has a debt-to-equity ratio of 2.15, a current ratio of 5.65 and a quick ratio of 5.18.

Neuronetics (NASDAQ:STIM) last released its quarterly earnings data on Tuesday, May 7th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.06. The company had revenue of $17.42 million for the quarter, compared to analyst estimates of $17.10 million. Neuronetics had a negative return on equity of 75.84% and a negative net margin of 37.61%. As a group, equities research analysts anticipate that Neuronetics, Inc. will post -0.91 earnings per share for the current year.

Institutional Investors Weigh In On Neuronetics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Assenagon Asset Management S.A. boosted its position in shares of Neuronetics by 63.0% in the second quarter. Assenagon Asset Management S.A. now owns 135,746 shares of the company’s stock valued at $244,000 after acquiring an additional 52,450 shares during the period. FourWorld Capital Management LLC bought a new position in Neuronetics in the 1st quarter valued at $171,000. Silvercrest Asset Management Group LLC boosted its holdings in Neuronetics by 4.6% in the 1st quarter. Silvercrest Asset Management Group LLC now owns 1,178,365 shares of the company’s stock valued at $5,609,000 after purchasing an additional 51,881 shares during the period. Dorsey & Whitney Trust CO LLC grew its position in shares of Neuronetics by 53.0% during the 1st quarter. Dorsey & Whitney Trust CO LLC now owns 48,652 shares of the company’s stock valued at $232,000 after purchasing an additional 16,855 shares in the last quarter. Finally, SG Americas Securities LLC bought a new position in shares of Neuronetics in the first quarter worth $62,000. 53.59% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, William Blair upgraded shares of Neuronetics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, May 14th.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.